人血白蛋白治疗急性胰腺炎的疗效及安全性的Meta分析

Efficacy and safety of human albumin for the treatment of acute pancreatitis:a Meta-analysis

目的系统评价人血白蛋白治疗急性胰腺炎(AP)的疗效与安全性。方法计算机检索PubMed、Web of Science、中国知网、维普资讯中文期刊服务平台和万方数据知识服务平台等数据库,纳入人血白蛋白治疗AP的随机对照试验与队列研究。筛选文献并进行质量评价后,采用RevMan 5.4软件进行Meta分析。结果最终纳入15篇文献,共2047例患者。Meta分析结果显示,与对照组相比,实验组患者腹痛、腹胀缓解所需时间及住院时间缩短,炎症相关指标水平,以及胰腺假性囊肿、腹腔积液及腹腔感染发生率降低(P<0.05)。但两组患者急性肾衰竭发生率差异无统计学意义(P>0.05)。结论人血白蛋白治疗可以缩短AP患者临床症状持续时间、降低炎症相关指标水平,缩短住院时间,改善患者预后,且不会增加相关并发症的发生风险。

Objective To systematically evaluate the efficacy and safety of human albumin for the treatment of acute pancreatitis(AP).Methods The databases of PubMed,Web of Science,China National Knowledge Infrastructure,VIP,and Wanfang Data Knowledge Service Platform were retrieved by computer for enrolling randomized controlled trials and cohort studies of human albumin for treating AP.After literature screening and quality evaluation,Meta-analysis was performed by using RevMan 5.4 software.Results A total of 15 literature was eventually enrolled,and there were 2047 patients.The results of Meta-analysis revealed that compared with the control group,the experiment group exhibited shorter time for relief of abdominal pain and distension,shorter time for length of hospital stay,decreased levels of inflammation-related indices,and decreased incidence rates of pancreatic pseudocyst,seroperitoneum,and abdominal infection(P<0.05).However,no statistically significant difference in the incidence rate of acute kidney failure was found between the two groups(P>0.05).Conclusion Human albumin therapy can shorten duration of clinical symptoms sustaining in AP patients,decrease levels of inflammation-related indices,shorten length of hospital stay,ameliorate patients′prognosis,and dose not increase occurrence risk of related complications.